GE HealthCare Announces Availability of Next-Generation bkActiv for Guiding Urology, Colorectal and Pelvic Floor Surgeries

Summation

  • With the acquisition of BK Medical in 2021, GE HealthCare adds the fast-growing field of real-time surgical visualization to its pre- and post-operative ultrasound capabilities, creating an end-to-end offering through the full continuum of care.
  • With this addition, the bkActiv now supports next level image quality of the prostate, kidney, and bladder, and has sensitive color doppler to visualize and measure the speed and direction of blood flow during the most complex surgical procedures.
  • “By expanding the bkActiv system, we are giving physicians the tools they need to provide precise treatment with the ability to see fine details in image guidance, which ultimately may allow for better outcomes for people who require urology, colorectal and pelvic floor procedures,” said Urvi Vyas, General Manager, Surgical Visualization &.

GE HealthCare (Nasdaq: GEHC) announced today the next-generation bkActiv is now available for guiding urology, colorectal and pelvic floor surgical procedures. The flagship intraoperative ultrasound imaging system, developed by BK Medical – a subsidiary of GE HealthCare, was designed to deliver high-performance ultrasound guidance with a simplified, intuitive user experience for surgeons. The bkActiv’s automatic no-touch autogain and advanced algorithms provide unmatched image quality, enabling confident decision making during surgical procedures. The system allows for minimal user interaction so that surgeons can focus on their patients.

“By expanding the bkActiv system, we are giving physicians the tools they need to provide precise treatment with the ability to see fine details in image guidance, which ultimately may allow for better outcomes for people who require urology, colorectal and pelvic floor procedures,” said Urvi Vyas, General Manager, Surgical Visualization & Guidance, Ultrasound at GE HealthCare, “We are proud to be the trusted partner for surgeons around the world given our long history of leadership in imaging and innovation.”

The bkActiv is a high-performance imaging system that allows for detailed, real-time surgical visualization, refined through decades of research, real-world use, and extensive user feedback. With this addition, the bkActiv now supports next level image quality of the prostate, kidney, and bladder, and has sensitive color doppler to visualize and measure the speed and direction of blood flow during the most complex surgical procedures. Combined with the new advanced portfolio of specialized, sterilizable transducers, needle guides, and procedure packs, the solution is designed to assist surgeons from simple procedures, such as biopsies, to the most advanced robotic surgeries.

The system’s features are designed with the physician in mind, and include:

  • Intuitive design with True-Sense touch technology and Smart Button that allow surgeons to operate the system with one hand for full control during the procedure
  • Advanced transducer portfolio including robotic and laparoscopic transducers
  • Adjustable monitor mounted on a flexible arm that allows for optimal image viewing with landscape or portrait mode
  • Easy integration into a crowded operating room due to its minimal system footprint

With the acquisition of BK Medical in 2021, GE HealthCare adds the fast-growing field of real-time surgical visualization to its pre- and post-operative ultrasound capabilities, creating an end-to-end offering through the full continuum of care. GE HealthCare has a long history of ultrasound innovation and a successful track record of growing technology acquisitions.

For more information on the bkActiv system for Urology visit: https://www.bkmedical.com/systems/bkactiv-urology/

For more information on the bkActiv system for Colorectal Surgery visit: https://www.bkmedical.com/systems/bkactiv-colorectal-surgery/

More News

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

PharmaLogic Announces Opening of Radiopharmaceutical Production Facility in New York City

Acquired in 2022, the facility has undergone extensive renovations and boasts state-of-the-art equipment, signifying the companys significant investment in fostering the development of novel radiopharmaceuticals in the region.

By using this website you agree to accept Medical Device News Magazine Privacy Policy